Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | -12.60% |
| 10 | Nu-Med Plus | 1.82 Mn | 1.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,001.56% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -66.14% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 84.68% |
| Dec 31, 2021 | 71.70% |
| Sep 30, 2021 | 59.42% |
| Jun 30, 2021 | 54.91% |
| Mar 31, 2021 | 16.75% |
| Dec 31, 2020 | 42.85% |
| Sep 30, 2020 | -33.87% |
| Jun 30, 2020 | -22.25% |
| Mar 31, 2020 | 61.41% |